News Release More March 6, 2023 KYORIN and Sumitomo Pharma Enter into License Agreement of Vibegron in Taiwan and Other Asian Countries February 6, 2023 Summary of Consolidated Financial Results(For the third quarter ended December 31, 2022) [Japanese GAAP] February 6, 2023 Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Feb 6, 2023) - Supplementary Information November 9, 2022 KYORIN and SUSMED conclude Collaboration Research and Sales Agreement for development of DTx in Otolaryngology Field November 9, 2022 Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Nov 9, 2022) - Supplementary Information November 9, 2022 Summary of Consolidated Financial Results(For the second quarter ended September 30, 2022) [Japanese Standard] August 2, 2022 Notice Regarding Decision on Termination and Dissolution of Business in Consolidated Subsidiaries, ActivX Biosciences, Inc. August 2, 2022 First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Aug 2, 2022) - Supplementary Information Latest IR Events More Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 Summary of consolidated Financial Results [ PDF 187.2 KB ] Supplementary Information [ PDF 551.0 KB ] Top Message Products Under Development IR Events Financial Information Financial Highlights Financial Indicators Business Segment/Main Products Cash Flows Capital Investment/Depreciation/R&D Costs Download Financial Data IR Library Summary of ConsolidatedFinancial Results/Presentation Document Annual Report Stock Information Shareholders Meeting Shareholder Return/Dividends General Information Stock Quote Business Risks Disclaimer FAQ Disclosure Policy
